159 related articles for article (PubMed ID: 37116378)
1. Hybrid peptides as platform for synchronized combination therapy.
Ashrafichoobdar E; Perez T; Ayalew L; Gorbanwand V; Monroy J; Slowinska K
Colloids Surf B Biointerfaces; 2023 Jun; 226():113326. PubMed ID: 37116378
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
Vale N; Pereira M; Santos J; Moura C; Marques L; Duarte D
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613510
[TBL] [Abstract][Full Text] [Related]
3. Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting.
Tang B; Zaro JL; Shen Y; Chen Q; Yu Y; Sun P; Wang Y; Shen WC; Tu J; Sun C
J Control Release; 2018 Jun; 279():147-156. PubMed ID: 29653223
[TBL] [Abstract][Full Text] [Related]
4. The Limitations of Collagen/CPP Hybrid Peptides as Carriers for Cancer Drugs to FaDu Cells.
Ho K; Morfin C; Slowinska K
Molecules; 2019 Feb; 24(4):. PubMed ID: 30769789
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer.
Houdaihed L; Evans JC; Allen C
Mol Pharm; 2018 Sep; 15(9):3672-3681. PubMed ID: 29863881
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
Yuan M; Qiu Y; Zhang L; Gao H; He Q
Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
[TBL] [Abstract][Full Text] [Related]
7. Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Zhang RX; Zhang T; Chen K; Cheng J; Lai P; Rauth AM; Pang KS; Wu XY
J Vis Exp; 2017 Oct; (128):. PubMed ID: 29053672
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.
Sudha T; Bharali DJ; Yalcin M; Darwish NH; Debreli Coskun M; Keating KA; Lin HY; Davis PJ; Mousa SA
Int J Nanomedicine; 2017; 12():1305-1315. PubMed ID: 28243091
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
10. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
Ryu JS; Kratz F; Raucher D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
[TBL] [Abstract][Full Text] [Related]
11. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')
Jin C; Bai L; Lin L; Wang S; Yin X
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1076-1084. PubMed ID: 28776396
[TBL] [Abstract][Full Text] [Related]
13. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
14. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
15. A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer.
Wang X; Chen X; Yang X; Gao W; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Dai Z; Zhang Q
Nanomedicine; 2016 Feb; 12(2):387-97. PubMed ID: 26711969
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
17. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment.
Duong HH; Yung LY
Int J Pharm; 2013 Sep; 454(1):486-95. PubMed ID: 23792465
[TBL] [Abstract][Full Text] [Related]
18. High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
Zhang L; Wang Y; Yang Y; Liu Y; Ruan S; Zhang Q; Tai X; Chen J; Xia T; Qiu Y; Gao H; He Q
ACS Appl Mater Interfaces; 2015 May; 7(18):9691-701. PubMed ID: 25845545
[TBL] [Abstract][Full Text] [Related]
19. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
